Baillie Gifford & Co’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,089,393
| Closed | -$20.9M | – | 290 |
|
|
2026
Q1 | $20.9M | Sell |
1,089,393
-56,123
| -5% | -$1.22M | 0.02% | 179 |
|
|
2025
Q4 | $25.2M | Buy |
1,145,516
+24,921
| +2% | +$450K | 0.02% | 178 |
|
|
2025
Q3 | $13.6M | Sell |
1,120,595
-5,133
| -0.5% | -$69.5K | 0.01% | 214 |
|
|
2025
Q2 | $21M | Buy |
1,125,728
+393,154
| +54% | +$7.79M | 0.02% | 187 |
|
|
2025
Q1 | $14M | Sell |
732,574
-13,535
| -2% | -$396K | 0.01% | 199 |
|
|
2024
Q4 | $26.9M | Buy |
746,109
+523,843
| +236% | +$17.7M | 0.02% | 172 |
|
|
2024
Q3 | $9.43M | Sell |
222,266
-120
| -0.1% | -$5.09K | 0.01% | 214 |
|
|
2024
Q2 | $8.96M | Sell |
222,386
-37,311
| -14% | -$1.56M | 0.01% | 219 |
|
|
2024
Q1 | $9.2M | Sell |
259,697
-2,946
| -1% | -$78.9K | 0.01% | 229 |
|
|
2023
Q4 | $7.77M | Sell |
262,643
-113
| -0% | -$2.34K | 0.01% | 231 |
|
|
2023
Q3 | $5.46M | Hold |
262,756
| – | – | 0.01% | 232 |
|
|
2023
Q2 | $6.45M | Sell |
262,756
-187
| -0.1% | -$6.02K | 0.01% | 236 |
|
|
2023
Q1 | $10.7M | Sell |
262,943
-141
| -0.1% | -$5.84K | 0.01% | 218 |
|
|
2022
Q4 | $11.8M | Hold |
263,084
| – | – | 0.01% | 210 |
|
|
2022
Q3 | $12.6M | Sell |
263,084
-43,139
| -14% | -$2.37M | 0.01% | 204 |
|
|
2022
Q2 | $18.1M | Sell |
306,223
-27,578
| -8% | -$2.26M | 0.02% | 196 |
|
|
2022
Q1 | $38.8M | Sell |
333,801
-23,151
| -6% | -$2.7M | 0.03% | 186 |
|
|
2021
Q4 | $53.7M | Buy |
356,952
+9,900
| +3% | +$1.34M | 0.03% | 178 |
|
|
2021
Q3 | $41.4M | Buy |
347,052
+127
| +0% | +$14K | 0.02% | 195 |
|
|
2021
Q2 | $33.8M | Buy |
346,925
+168
| +0% | +$15K | 0.02% | 208 |
|
|
2021
Q1 | $30.6M | Buy |
346,757
+51,312
| +17% | +$4.77M | 0.02% | 207 |
|
|
2020
Q4 | $28.3M | Buy |
295,445
+176
| +0.1% | +$18.1K | 0.02% | 186 |
|
|
2020
Q3 | $33.5M | Hold |
295,269
| – | – | 0.02% | 168 |
|
|
2020
Q2 | $29.2M | Sell |
295,269
-139,431
| -32% | -$11.1M | 0.02% | 158 |
|
|
2020
Q1 | $28M | Hold |
434,700
| – | – | 0.03% | 133 |
|
|
2019
Q4 | $25.9M | Hold |
434,700
| – | – | 0.03% | 148 |
|
|
2019
Q3 | $25.6M | Hold |
434,700
| – | – | 0.03% | 146 |
|
|
2019
Q2 | $28M | Hold |
434,700
| – | – | 0.03% | 149 |
|
|
2019
Q1 | $27.6M | Hold |
434,700
| – | – | 0.03% | 148 |
|
|
2018
Q4 | $16.5M | Hold |
434,700
| – | – | 0.02% | 163 |
|
|
2018
Q3 | $18.6M | Buy |
+434,700
| New | +$15.2M | 0.02% | 159 |
|
Other funds holding TNDM
PIM
YIH
AIMCA
Baillie Gifford & Co's TNDM Position: Q2 2026 in Review
Baillie Gifford & Co sold out of Tandem Diabetes Care (TNDM) in Q2 2026, closing a stake of 1,089,393 shares — an estimated $20.9M sold.
Baillie Gifford & Co first reported a position in TNDM in Q3 2018 and held it in 31 quarters. The position peaked at $53.7M in Q4 2021. 102 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.
- Baillie Gifford & Co reported no remaining Tandem Diabetes Care position as of Q2 2026 after selling out during the quarter.
- Baillie Gifford & Co sold 1,089,393 Tandem Diabetes Care shares in Q2 2026, an estimated $20.9M.
- Baillie Gifford & Co first reported a position in Tandem Diabetes Care in Q3 2018 and held it in 31 quarters.
- Baillie Gifford & Co's Tandem Diabetes Care position peaked at $53.7M in Q4 2021.
- 102 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.
Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.